Drugs / Neramexane
Neramexane
Trials 15
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 17 trials | ||||||
| Phase 1 | NCT01109680 | Apr → Jun 2010 | — | Merz Pharmaceuticals GmbH | Completed | No outcome recorded |
| Phase 1 | NCT00972127 | Oct → Dec 2009 | — | Merz Pharmaceuticals GmbH | Completed | No outcome recorded |
| Phase 1 | NCT00978614 | Sep 2009 → Apr 2010 | — | Merz Pharmaceuticals GmbH | Completed | No outcome recorded |
| Phase 1 | NCT00983099 | Sep 2009 → Sep 2010 | — | Merz Pharmaceuticals GmbH | Completed | No outcome recorded |
| Phase 1 | NCT00955760 | Aug → Dec 2009 | — | Merz Pharmaceuticals GmbH | Completed | No outcome recorded |
| Phase 1 | NCT00936026 | Jul → Dec 2009 | — | Merz Pharmaceuticals GmbH | Completed | No outcome recorded |
| Phase 1 | NCT00915174 | Jun → Nov 2009 | — | Merz Pharmaceuticals GmbH | Completed | No outcome recorded |
| Phase 23 trials · 1 missed | ||||||
| Phase 2 | NCT00799942 | May 2009 → ? | congenital nystagmus, multiple sclerosis | Merz Pharmaceuticals GmbH | Terminated | No outcome recorded |
| Phase 2 | NCT00661440 | May 2008 → ? | congenital nystagmus | Merz Pharmaceuticals GmbH | Completed | No outcome recorded |
| Phase 2 | NCT00405886 | Oct 2005 → Mar 2007 | tinnitus | Merz Pharmaceuticals GmbH | Completed | Missed primary |
| Phase 35 trials | ||||||
| Phase 3 | NCT00955799 | Sep 2009 → May 2011 | tinnitus | Merz Pharmaceuticals GmbH | Completed | No outcome recorded |
| Phase 3 | NCT00827008 | Jan 2009 → Dec 2011 | tinnitus | Merz Pharmaceuticals GmbH | Terminated | No outcome recorded |
| Phase 3 | NCT00772980 | Nov 2008 → Jun 2010 | tinnitus | Merz Pharmaceuticals GmbH | Completed | No outcome recorded |
| Phase 3 | NCT00739635 | Sep 2008 → Feb 2010 | tinnitus | Merz Pharmaceuticals GmbH | Completed | No outcome recorded |
| Phase 3 | NCT00090116 | Mar 2003 → Mar 2005 | Alzheimer disease | Forest Laboratories | Completed | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 1 | NCT00712283 Comparator | Jul 2008 → Mar 2009 | — | Merz Pharmaceuticals GmbH | Completed | No outcome recorded |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 17 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Neramexane | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00405886 ↗ |
| Known as | Neramexane mesilate | ChEMBL registry synonym — accepted as the source's own label CHEMBL2110954 ↗ |
| Known as | Neramexane Mesylate | “Evaluation of Pharmacokinetics, Safety and Tolerability of Single and Multiple Oral Doses of Neramexane Mesylate in Healthy Japanese Subjects” NCT00983099 ↗2“Double-blind treatment period of 29 weeks up to 75 mg Neramexane mesylate per day” NCT00955799 ↗ “Drug: Neramexane mesylate” NCT00712283 ↗ |
| Known as | Neramexano | ChEMBL registry synonym — accepted as the source's own label CHEMBL2110954 ↗ |
| Action | Inhibit | “blocks the effects of excessive glutamate at the receptor (NMDA receptor antagonist)” NCT00090116 ↗ |
| Modality | Small molecule | — CHEMBL2110954 ↗ |
| Route | Oral | “Oral tablets, duration: 16 weeks” NCT00405886 ↗ |